subscribeSubscribe
Enforcement Report - Week of September 13, 2023

Enforcement Report - Week of September 13, 2023
FDA
13 Sep 2023
Share Share
Enforcement Report - Week of March 15, 2023

Enforcement Report - Week of March 15, 2023
FDA
15 Mar 2023
Share Share
Initiator Pharma obtains approval to begin trial for pain-reducing effects

Initiator Pharma obtains approval to begin trial for pain-reducing effects
CLINICALTRIALSARENA
27 Nov 2021
Share Share
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA

Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA
PR NEWSWIRE
19 Dec 2019
Share Share
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin)

Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin)
PR NEWSWIRE
18 Dec 2019
Share Share
Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent

Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent
GLOBE NEWSWIRE
03 Dec 2019
Share Share
Kindler`s Centrexion restarts IPO bid to fund phase 3 pain trial

Kindler`s Centrexion restarts IPO bid to fund phase 3 pain trial
Nick P. Taylor FIERCE BIOTECH
20 Sep 2019
Share Share
Grunenthal Acquires Averitas Pharma, Establishes Commercial Footprint in the US

Grunenthal Acquires Averitas Pharma, Establishes Commercial Footprint in the US
BIOSPACE
14 Nov 2018
Share Share
Grünenthal Acquires Global Rights for Qutenza®

Grünenthal Acquires Global Rights for Qutenza®
PR NEWSWIRE
05 Nov 2018
Share Share
Enforcement Report - Week of May 30, 2018

Enforcement Report - Week of May 30, 2018
FDA
29 May 2018
Share Share